Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used in the treatment of non-small cell lung cancer (NSCLC), while an acneiform rash is one of the most common adverse events in patients taking them.[1] Such eruptions are often manifested as pustular lesions in scalp, face, upper chest, and back with or without pruritus or tenderness, mostly appearing in 1 to 2 weeks after using EGFR-TKIs.[2,3] Unfatal as acneiform is 9, clinical benefits of EGFR-TKIs are undermined for its damage to patient's appearance, quality of life, and treatment adherence.[4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.